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Follow-up care amongst long-term childhood cancer survivors:
A report from the Swiss Childhood Cancer Survivor Study
Abstract
In the Swiss Childhood Cancer Survivor Study, we aimed to assess the proportion of long-term
survivors attending follow-up care, to characterise attendees and to describe the health professionals
involved. We sent a questionnaire to 1252 patients, of whom 985 (79%) responded, aged in average
27years (range 20-49). Overall, 183 (19%) reported regular, 405 (41%) irregular and 394 (40%) no
follow-up. For 344, severity of late effects had been classified in a previous medical examination. Only
17% and 32% of survivors with moderate and severe late effects respectively had made regular visits a
decade later. Female gender, after a shorter time since diagnosis, had radiotherapy, and having suffered
a relapse predicted follow-up. In the past year, 8% had seen a general practitioner only, 10% a paediatric
or adult oncologist and 16% other health specialists for a cancer related problem. These findings
underline the necessity to implement tailored national follow-up programmes.
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ABSTRACT  
 
In the Swiss Childhood Cancer Survivor Study, we aimed to assess the proportion of 
long-term survivors attending follow-up care, to characterize attendees and to 
describe the health professionals involved. We sent a questionnaire to 1252 patients, 
of whom 985 (79%) responded, aged in average 27 years (range 20 to 49). Overall, 
183 (19%) reported regular, 405 (41%) irregular and 394 (40%) no follow-up. For 
344, severity of late effects had been classified in a previous medical examination. 
Only 17% and 32% of survivors with moderate and severe late effects respectively 
had regular visits a decade later. Female gender, a shorter time since diagnosis, 
radiotherapy, and having suffered a relapse predicted follow-up. In the past year, 8% 
had seen a general practitioner only, 10% a paediatric or adult oncologist and 16% 
other health specialists for a cancer related problem. These findings underline the 
necessity to implement tailored national follow-up programs. 
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INTRODUCTION 
 
Organization of long-term follow-up for childhood cancer survivors has become an 
important issue. Due to dramatic therapeutic improvements during past decades, 
survival rates in childhood cancer reached more than 80%(1) resulting in a growing 
population of long-term survivors.(2) However, two thirds of survivors have at least 
one chronic condition, with one third being classified as severe or life threatening.(3-
5) Long-term follow-up aims to reduce late complications of childhood cancer by early 
diagnosis and management.(2, 6) In addition, it allows provision of psychosocial 
support and lifestyle counselling.(7) Routinely updated evidence-based guidelines 
are available recommending individual screening of potential late consequences 
according to treatment received,(8-10) with life-long follow-up recommended for 
patients who received radiotherapy.(8) Importantly, survivors who have developed 
late effects should remain in regular care.(7) 
 
Little is known, if and how these recommendations are put into practice. Studies in 
the US, UK and Canada reported that contrary to recommendations, only one third of 
survivors received regular long-term follow-up.(11-13) In Switzerland and elsewhere, 
the implementation of follow-up programs for long-term survivors remains a 
challenge. The Swiss Paediatric Oncology Group (SPOG) has published 
recommendations for a standardized assessment of late effects in 1996 suggesting 
to involve medical oncologists and general practitioners to assure a seamless 
transition from paediatric to adult care.(5-6) However, it is unknown how these 
recommendations have been implemented into practice, what proportion of survivors 
really attend long-term follow-up and where they go. The Swiss health care system 
has a compulsory national health insurance, with premiums for disadvantaged 
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citizens subsidized by the government. This should guarantee equal access to all 
treatments.   
 
In this study, we aimed 1) to assess the proportion of long-term childhood cancer 
survivors attending follow-up, considering severity of late effects, 2) to characterize 
follow-up attendees and 3) identify the health professionals involved. 
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PATIENTS AND METHODS 
 
Study population 
The Swiss Childhood Cancer Registry (SCCR) is a population-based registry 
including all children and young people diagnosed with leukaemia, lymphoma, central 
nervous system (CNS) tumours, malignant solid tumours or Langerhans cell 
histiocytosis (LCH) before the age of 16 years.(14-15)  
 
Nested in the SCCR, the Swiss Childhood Cancer Survivor Study (SCCSS) is a 
nationwide long-term follow-up study that started in 2007 and includes all registered 
patients who were diagnosed since 1976 and survived at least 5 years. For the 
current analysis we included all survivors aged 20 years or over at the time of survey, 
more than 10 years after diagnosis (n=1280). 
 
A subgroup of eligible survivors (n=478) had participated in a standardized medical 
examination during the 1990s to detect late effects.(5, 16) The examination included 
medical history, clinical examination, neuropsychological testing and laboratory 
investigations. Severity of late effects was graded from 0 to 4 (see Appendix II: Table 
1 for definitions and examples): with grade 0 “no late effects”; grade 1 “asymptomatic, 
not requiring therapy for late effects” (=mild, e.g. scar); grade 2 “late effects needing 
continuous medical follow-up“ (=moderate, e.g. hypothyroidism); grade 3 “physical or 
mental sequelae, not likely to be improved by therapy” (=severe, e.g. cognitive 
deficits limiting schooling); and grade 4 “severely handicapping late effects, leaving 
patients unable to work independently” (=very severe).(5)  
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Ethical approval for this study was obtained from the general cancer registry 
permission of the SCCR (The Swiss Federal Commission of Experts for Professional 
Secrecy in Medical Research) and a non-obstat statement was obtained from the 
ethics committee of the canton of Bern.  
 
Procedure 
All survivors received a study information letter from their former treating centre, with 
the option to decline, report address changes or request the questionnaire in another 
language (German, French and Italian). Survivors wishing to take part in the study 
were sent a copy of the questionnaire with a pre-paid return envelope. Reminder 
letters were sent to non-responders two months later. If they did not return the 
questionnaire at this stage, they were contacted by telephone to answer a shortened 
version.  
 
Measures  
Baseline demographic information together with prospectively collected medical 
information on diagnosis and treatment was extracted from the SCCR. Diagnosis was 
classified according to the International Classification of Childhood Cancer.(17) For 
the analysis, diagnostic groups with less than 5% survivors were merged. Treatment 
options included surgery only, chemotherapy (without radiotherapy, may have had 
surgery), radiotherapy (may have had surgery or chemotherapy), and participants 
were coded accordingly. 
 
We used a standardized questionnaire derived from childhood cancer survivor 
studies in the US and UK.(18-19) Furthermore, we included specific socio-
demographic measures for comparison with the Swiss population. The main domains 
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of the questionnaire were: quality of life, somatic health, current medication and 
health service utilization, psychological distress, health behaviour, and socio-
economic information.  
 
To assess the proportion of survivors attending follow-up, we first asked whether they 
still attended follow-up for their cancer. Possible answers included: yes, at the 
treatment centre; yes, elsewhere (both coded as regular follow-up); no, but sees a 
doctor every now and then for a medical check-up (coded as irregular follow-up); and 
no, has not seen a doctor for a while. We also asked participants to select which 
health professionals they had seen in the past year from a list and whether these 
visits were related to cancer or not (Appendix II: Questions used in questionnaire 
(English translation); questionnaire is available at 
http://www.childhoodcancerregistry.ch/index.php?id=2849).  
 
General health status and physical pain were measured with item 1 and item 7 of the 
Short Form 36 (SF36).(20) Survivors were also asked if they experienced any late 
effects of their cancer or treatment. Socio-economic status was measured by 
education. We grouped parents’ and survivors’ own education into four categories: 
“compulsory schooling”, “vocational training”, “upper secondary education” (including 
high school, teachers training colleges, technical colleges and upper vocational 
education) and “university education”. Survivors were asked whether they had 
received recommendations for follow-up; either a medical checklist or a copy of their 
discharge letter. Furthermore, we asked if they had actively searched for further 
information on their former disease after discharge using any of the following 
sources: physician, internet, technical books or reports, friends, survivor associations 
or others.   
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Statistical analysis 
We used Stata version 10 (Stata Corporation, Austin, Texas) for all analyses. 
Differences between responders and non-responders were assessed using chi2- and 
Kruskal Wallis trend tests. Factors associated with attending follow-up in the 
univariate analysis (p<0.05) were assessed in two different logistic regression 
models. Firstly we included factors from the SCCR collected at the time of diagnosis. 
In a second model, we looked at factors assessed in the survey simultaneously to the 
information on follow-up attendance, to characterize the attendees. Both models 
were also repeated using multinomial logistic regression comparing non-attendees 
with irregular and regular follow-up attendees separately. 
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RESULTS 
Of the 1441 eligible survivors a valid address was found for 1252 (87%). Among 
these, 985 (79%) returned the questionnaire (Figure 1) including 71 survivors who 
only answered the shortened questionnaire. Responders did not differ from non-
responders regarding diagnosis and therapy, but were more often female and 
German speaking (Table 1). Response-rate varied across treatment centres from 
71% to 88%. Survivors’ mean age at the time of survey was 27.2 years (range 20 to 
49 years) and the mean time elapsed since diagnosis was 20.6 years (10 to 44 
years). 
 
Use of long-term follow-up by severity of late effects 
Of the 985 survivors, 588 (60%) reported to have follow-up; 183 (19%) attended 
regular and 405 (41%) irregular follow-up. Within the sub sample of survivors for 
whom severity of late effects was assessed in a previous examination, 59/126 (47%) 
of those with grade 0, 46/88 (52%) of those with grade 1, 56/92 (61%) of those with 
grade 2, 13/19 (68%) of those with grade 3 and 4/4 (100%) of those with grade 4 late 
effects attended follow-up (trend test p<0.001). Visits in regular intervals were 
reported by 9 (7%), 7 (8%), 16 (17%), 6 (32%), and 3 (75%) of those graded as 0, 1, 
2, 3 and 4 respectively.   
 
Characteristics of follow-up attendees 
Factors associated with use of follow-up were determined in two separate models. 
First, we assessed which factors predicted follow-up attendance, by looking at 
information assessed at the time of diagnosis (Table 2). Females were more likely to 
attend follow-up than males, (odds ratio (OR)=1.42). Survivors with more than 20 
years since diagnosis were less likely to have follow-up than survivors with a shorter 
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time since diagnosis (OR=0.48). Also treatment modalities predicted use of follow-up: 
71% of survivors treated with radiotherapy and 54% of those with chemotherapy but 
no radiotherapy attended follow-up, compared to 42% of those with surgery only 
(OR=2.12 and 3.81). Survivors with a relapse history were more likely to attend 
(OR=1.92). Results were similar when comparing regular attendees and irregular 
attendees separately to non-attendees in a multinomial regression model, with 
somewhat larger effect sizes for regular attendees (Appendix II: Table 2).  
 
Second, we examined characteristics of attendees assessed at the time of the survey 
(Table 3). In the multivariable model attendees were more likely to report late effects 
from their cancer treatment (OR=2.50) and to have actively sought for information 
about their former disease after discharge (OR=1.78; information from physician: 
30% of attendees vs. 15% of non-attendees; internet: 20% vs. 14%; technical 
books/magazines: 21% vs. 12%). Socio-economic determinants such as level of 
education of survivors and having a partner were not associated. Results of the 
multinomial regression model were again comparable, with larger effect sizes for 
regular than for irregular attendees, when both were compared to non-attendees 
(Appendix II: Table 3). 
 
Health care professionals involved in long-term follow-up  
In total, 764 of 914 survivors (84%) reported having visited a health professional in 
the past year and 312 (34%) said that the visit had been caused by a problem related 
to their former disease. Of 638 survivors (70% of 914) who had seen a general 
practitioner in the past year, 164 survivors (22%) had a cancer-related visit (Figure 
2). Eighteen percent of female survivors (79 of 439) reported a cancer-related visit at 
the gynaecologist in the past year and 9% (n=80) of survivors had seen a 
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psychologist because of problems related to their cancer. We then grouped cancer-
related visits into three different models of follow-up.(21) Of the 914 survivors, 76 
(8%) had seen a general practitioner only, 90 (10%) had consulted a paediatric or 
adult oncologist, and 146 (16%) had seen other physicians (some of these had also 
gone to a general practitioner) (Figure 3). In the follow-up of survivors of Hodgkin 
lymphoma, oncologists were most often involved (16 of 80, 20%) whereas survivors 
of brain tumours mostly attended follow-up at other specialists such as 
endocrinologists, neurologists, ophthalmologists and psychologists (38 of 100, 38%).
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DISCUSSION 
This nationwide long-term follow-up study found that only 19% of long-term survivors 
of childhood cancer had regular follow-up visits, with an additional 41% reporting 
irregular visits. Although the proportion of survivors attending follow-up increased 
with severity of late effects, only a minority of those judged as needing long-term 
follow-up at a previous medical examination still attended regular visits a decade 
later. In the past year 34% of survivors had sought medical help for a problem related 
to their former disease, most often from a general practitioner.  
 
Comparison of the proportion of follow-up attendees with other countries 
Direct comparisons are difficult since studies on use of follow-up included differing 
times elapsed since diagnosis (Appendix II: Table 4).(11-13, 22) Nevertheless, 
similarly low proportions attended follow-up in other countries: in the UK 35% of 
survivors were still on regular long-term hospital follow-up 5 or more years off 
treatment.(11) In the Childhood Cancer Survivor Study (CCSS) from the US, 32% 
reported ongoing care for their prior cancer.(12) Also in Sweden, only 40% of long-
term survivors had recently attended or were scheduled for a follow-up.(23) These 
proportions are low considering the high cumulative incidence of chronic health 
conditions 25 years after the diagnosis with two thirds of survivors suffering from late 
effects, and are not in accordance with recommendations.(2, 4) Nevertheless, similar 
to the findings of the recent CCSS study,(12) the majority of Swiss survivors received 
some form of medical care in the past year.  
 
In our study, the proportions of survivors having follow-up increased with severity of 
their late effects. In Switzerland and elsewhere an annual follow-up of all survivors 
might neither be possible nor necessary. A relatively simple three-level model of risk-
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stratification based on diagnosis and treatment has therefore been proposed.(24) 
Survivors with moderate or severe late effects are likely to profit from medical care in 
a regular follow-up. Similar to our findings, a recent report from the CCSS showed a 
higher probability to receive risk-based care for survivors with a severe, life 
threatening or disabling chronic health condition.(12) However, in our study, a 
substantial proportion of survivors, even those with moderate or severe late effects, 
which would require regular follow-up or therapy, reported to not attend ten years 
later. 
 
Factors associated with follow-up  
In accordance with studies from other countries, likelihood to attend follow-up 
decreased with longer time since diagnosis,(13, 22) younger age at diagnosis and 
older age at interview.(12) This is in contrast with other findings showing that the 
cumulative incidence of adverse health conditions among survivors increases with 
time and does not appear to plateau.(4) Beyond 45 years from diagnosis survivors 
were still at increased risk of premature death, due to second primary cancers, 
circulatory, cardiac and respiratory causes.(25) Similar to previous studies, follow-up 
was more common in children with high risk treatment including radiotherapy.(12-13, 
22) but not associated with initial diagnosis after adjusting for treatment.(26-27) 
Survivors from bone tumours were more likely to have seen an oncologist than 
survivors of leukaemia.(13) In contrast with other studies, we found that females were 
more likely to attend.(11-12, 23, 26-27) Survivors’ educational background was not 
associated with follow-up attendance, as in other studies.(12, 22)  
Considering all this, it seems that problems associated with long-term follow-up are 
seen in different continents and different health care models, including health care 
systems that should guarantee equal access to treatment to all patients, including the 
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poorest. This suggests that characteristics of the health systems may not be the most 
important barriers to access of follow-up for young adult survivors of childhood 
cancer.  
Insufficient knowledge of survivors about their diagnosis, treatment and potential late 
consequences has been described as a major barrier to follow-up.(28-29) We found 
that only 25% of study participants had ever received a written document with 
recommendations for future care. In addition, survivors’ own interest in their disease, 
as shown by active search for further information, was strongly associated with 
follow-up attendance. Physicians should be aware of their role as important 
information source for long-term survivors. However, results also show that the 
Internet played an important role. Websites with evidence-based information 
specifically for survivors and ideally maintained by professionals therefore need to be 
developed. 
 
Health professionals involved in follow-up  
Different models have been proposed to facilitate the transition from paediatric to the 
adult care in childhood cancer survivors.(21) Our results showed that similar to the 
UK and US, general practitioners were frequently involved in long-term care of 
childhood cancer survivors and saw the largest number of patients (n=164, 26%).(11, 
22) Thus, a follow-up model with general practitioners as gatekeepers transferring 
patients to specialists may cover best the needs of a majority of patients. However, 
preferences and views of survivors and physicians, as well as specific features of the 
health system need to be considered. A UK study for instance reported that survivors 
highly appreciated clinic-based cancer-specific care.(30) 
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Many different health care professionals were involved in long-term follow-up of 
childhood cancer survivors in our study, but contrary to recommendations paediatric 
oncologists played a modest role.(5-6) Survivors of Hodgkin’s lymphoma often 
consulted oncologists, while brain tumour survivors went to endocrinologists, 
neurologists, ophthalmologists and psychologists. These consultations at many 
different specialists highlight the need for close collaboration between physicians. 
Specialized multidisciplinary survivor programs may cover these needs best.(31) 
 
Methodological considerations 
The SCCSS is a nationwide representative cohort study investigating long-term 
outcome of childhood cancer in Switzerland. The following limitations have to be 
considered: first, our data are self-reported. Survivor’s opinions on whether or not 
health visits in the past year were cancer-related might not always correspond with 
the opinion of their health care providers. Second, the medical examination of the 
sub sample of study participants had been more than a decade before the current 
survey, and may not be representative for the entire study population. Some formerly 
asymptomatic patients may have developed late effects since, and severity grades 
may have increased rather than decreased over time as transient problems were not 
coded as late effects and severe conditions were unlikely to be improved by therapy.  
Third, our study design, where follow-up care and health outcomes were assessed at 
the same survey, does not allow to draw conclusions as to whether frequency or type 
of follow-up does influence incidence and severity of subsequently occurring late 
effects. This important question needs to be studied in a truly prospective design.  A 
major strength of the study is the population-based design, and the fact that we also 
assessed information on health care providers. The response rate was high, and our 
results should be representative for childhood cancer survivors in Switzerland, with 
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some caution for children diagnosed before 1990 when the Swiss Childhood Cancer 
Registry was less complete.(32) Variation in the response rate across treatment 
centres may reflect cultural differences in the French and German speaking part of 
Switzerland rather than differences in diagnosis or treatment of patients.  
 
Conclusion 
The study gave an overview on medical care of childhood cancer survivors in 
Switzerland and provides a basis for future research. Less than a fifth of survivors 
attended follow-up regularly and about a third irregularly. Strikingly only 60% of 
survivors diagnosed with moderate late effects 10 years ago, judged as requiring 
continued follow-up, had really attended. This contrasts with recommendations, and 
reasons for this remain unclear. In future studies, we plan to assess opinions, 
preferences and needs of survivors and health care providers as a basis for 
developing a national follow-up program tailored to the needs and preferences of 
those concerned. 
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Table 1: Characteristics of study population by response status 
 
Nonresponders 
(N=267)  All Responders (N=985)  
Subgroup of Responders 
with Medical Examination 
in 1994-96 (N=344) 
Characteristics n % 95%CI  n % 95%CI P-value* n % 95%CI 
Sex      0.001    
   Female 89 33.3 [27.6-39.0]  439 44.6 [41.5-47.7]  139 40.4 [35.2-45.6] 
   Male 178 66.7 [61.0-72.4]  546 55.4 [52.3-58.5]  205 59.6 [54.4-64.8] 
Age at diagnosis (yrs)           0.476      
   0 - 4  59 22.1 [17.1-27.1]  262 26.6 [23.8-29.4]  127 36.9 [31.8-42.0] 
   5 - 8  77 28.8 [23.4-34.3]  257 26.1 [23.3-28.8]  100 29.1 [24.2-33.9] 
   9 - 12  68 25.5 [20.2-30.7]  226 22.9 [20.3-25.6]  62 18.0 [13.9-22.1] 
 13 -15  63 23.6 [18.5-28.7]  240 24.4 [21.7-27.1]  55 16.0 [12.1-19.9] 
Time since diagnosis (yrs)     0.675   
 >10 - 20  128 47.9 [41.9-54.0]  471 47.8 [44.7-50.9]  70 20.3 [16.1-24.6] 
   21 - 30  126 47.2 [41.2-53.2]  450 45.7 [42.6-48.8]  247 71.8 [67.0-76.6] 
 >30 13 4.9 [2.3-7.5]  64 6.5 [5.0-8.0]  27 7.8 [5.0-10.7] 
Current age (yrs)           0.166      
   < 26  72 27.0 [21.6-32.3]  319 32.4 [29.5-35.3]  70 20.3 [16.1-24.6] 
   26 - 30  92 34.5 [28.7-40.2]  313 31.8 [28.9-34.7]  110 32.0 [27.0-36.9] 
   31 - 34  57 21.3 [16.4-26.3]  202 20.5 [18.0-23.0]  96 27.9 [23.1-32.7] 
   35+ 46 17.2 [12.7-21.8]  151 15.3 [13.1-17.6]  68 19.8 [15.5-24.0] 
Diagnosis     0.562   
   Leukaemia 88 33.0 [27.3-38.6]  379 38.5 [35.4-41.5]  158 45.9 [40.6-51.2] 
   Hodgkin's disease 30 11.2 [7.4-15.0]  87 8.8 [7.1-10.6]  18 5.2 [2.9-7.6] 
   Non-Hodgkin lymphomas 36 13.5 [9.4-17.6]  110 11.2 [9.2-13.1]  41 11.9 [8.5-15.4] 
   CNS tumours 30 11.2 [7.4-15.0]  108 11.0 [9.0-12.9]  18 5.2 [2.9-7.6] 
   Neuroblastoma 12 4.5 [2.0-7.0]  38 3.9 [2.7-5.1]  17 4.9 [2.6-7.2] 
   Retinoblastoma 4 1.5 [0.0-3.0]  19 1.9 [1.1-2.8]  5 1.5 [0.2-2.7] 
   Renal tumours 12 4.5 [2.0-7.0]  56 5.7 [4.2-7.1]  25 7.3 [4.5-10.0] 
   Malignant bone tumours 9 3.4 [1.2-5.5]  46 4.7 [3.4-6.0]  10 2.9 [1.1-4.7] 
   Soft tissue sarcomas 20 7.5 [4.3-10.7]  49 5.0 [3.6-6.3]  23 6.7 [4.0-9.3] 
   Other† 14 5.2 [2.6-7.9]  43 4.4 [3.1-5.6]  14 4.1 [2.0-6.2] 
   Langerhans cell histiocytosis 12 4.5 [2.0-7.0]  50 5.1 [3.7-6.4]  15 4.4 [2.2-6.5] 
Therapy         0.149      
   Surgery only 23 8.6 [5.2-12.0]  79 8.0 [6.3-9.7]  8 2.3 [0.7-3.9] 
   Chemotherapy‡ 118 44.2 [38.2-50.2]  501 50.9 [47.7-54.0]  201 58.4 [53.2-63.7] 
   Radiotherapy§ 126 47.2 [41.2-53.2]  405 41.1 [38.0-44.2]  135 39.2 [34.1-44.4] 
   Bone marrow transplant 9 3.4 [1.2-5.5]  36 3.7 [2.5-4.8]  6 1.7 [0.4-3.1] 
Language     0.005   
   German 179 67.0 [61.4-72.7]  748 75.9 [73.3-78.6]  270 78.5 [74.1-82.9] 
   French 74 27.7 [22.3-33.1]  212 21.5 [19.0-24.1]  72 20.9 [16.6-25.3] 
   Italian 14 5.2 [2.6-7.9]  25 2.5 [1.6-3.5]   2 0.6 [-0.2-1.4] 
  
Abbreviations: CNS, Central Nervous System; yrs, years 
* Chi square and trend test comparing nonresponders with responders 
† includes Hepatic tumours, Germ cell tumours and other rare tumours 
‡ Chemotherapy: Survivor had chemotherapy and may have had surgery but no radiotherapy 
§ Radiotherapy: Survivor had radiotherapy and may have had chemotherapy and surgery 
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Table 2: Baseline characteristics of survivors assessed at time of diagnosis, 
predicting use of follow-up  
 
Follow-up 
Attendees 
(n=588) 
  
Non 
Follow-up  
Attendees 
(n=394)     
  n %   n % 
OR 
unadjusted 95% CI p-value* 
OR† 
adjusted 95% CI p-value*
Sex           0.004    0.014
   Male 303 55.8   240 44.5 1.00    1.00   
   Female 285 64.9   154 35.1 1.47 [1.13-1.90]   1.42 [1.07-1.87]  
Age at diagnosis (yrs)    < 0.001  0.017
   0-4 143 54.8  118 45.4 1.00  1.00 
   5-8 134 52.3  122 47.9 0.91 [0.64-1.28]  0.77 [0.52-1.12]
   9-12 141 62.4  85 37.6 1.37 [0.95-1.97]  1.06 [0.69-1.61]
 >12 170 71.1  69 29.2 2.03 [1.40-2.95]  1.50 [0.96-2.35]
Time since diagnosis (yrs)           < 0.001    < 0.001
   11-20 316 67.2   154 32.9 1.00    1.00   
   21-30  233 52.0   215 48.2 0.53 [0.40-0.69]   0.48 [0.36-0.65]  
 >30 39 60.9   25 39.1 0.76 [0.44-1.30]   0.59 [0.33-1.07]  
Diagnosis    < 0.001  0.085
  Leukaemia 216 57.3  161 43.0 1.00  1.00 
  Hodgkin's disease 66 75.9  21 24.1 2.34 [1.38-3.99]  1.30 [0.70-2.39]
  Non-Hodgkin's lymphoma 61 55.5  49 44.5 0.93 [0.60-1.42]  0.81 [0.51-1.28]
  CNS tumours 73 67.6  35 32.4 1.55 [0.99-2.44]  1.33 [0.75-2.35]
  Embryonal tumours‡ 81 57.0  61 43.0 0.99 [0.67-1.46]  1.20 [0.78-1.84]
  Bone tumours/ STS 67 70.5  28 29.5 1.78 [1.10-2.90]  1.38 [0.82-2.32]
  Other§ 24 38.1  39 62.5 0.46 [0.27-0.79]  0.54 [0.29-0.99]
Therapy           < 0.001    < 0.001
   Surgery only 33 42.3   45 58.2 1.00    1.00   
   Chemotherapy** 270 53.9   231 46.1 1.59 [0.98-2.58]   2.12 [1.15-3.92]  
   Radiotherapy†† 285 70.7   118 29.6 3.29 [2.00-5.42]   3.81 [2.09-6.94]  
Relapse    < 0.001  0.001
  No 473 57.3  353 42.8 1.00  1.00 
  Yes 115 73.7  41 27.2 2.09 [1.43-3.07]  1.92 [1.28-2.89]
Parents' education‡‡           0.973     
  Compulsory schooling 59 60.8   38 39.2 1.02 [0.65-1.60]       
  Vocational training 256 60.4   168 39.6 1.00        
  Upper secondary§§ 145 58.2   104 41.8 0.91 [0.67-1.26]       
  University education 61 61.6   38 38.4 1.05 [0.67-1.65]       
Immigration***    0.093  
  No 437 58.2  314 41.8 1.00   
  Yes 135 64.6   74 35.4 1.31 [0.95-1.80]       
Abbreviations: OR, Odds Ratio;  CI, Confidence Interval; yrs, years; CNS, Central Nervous System; STS, Soft tissue sarcomas 
Row percentages are presented 
* Global p-value 
† Adjusted for all factors listed except parent's education and immigration 
‡ Includes neuroblastoma, retinoblastoma, Wilms tumour, liver tumour and germ cell tumour 
§ Includes epithelial neoplasms, malignant melanomas, unspecified malignant tumours and Langerhans cell histiocytosis 
** Some chemotherapy but no radiotherapy 
†† Some radiotherapy (may have had chemotherapy and surgery) 
‡‡ The highest completed education of either father or mother 
§§ Upper secondary education includes high school, teachers training colleges, technical colleges and upper vocational 
education 
*** Does not have a Swiss passport or has received the Swiss passport after date of birth or parents originate from another 
country 
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Table 3: Current characteristics of survivors assessed at the time of survey, 
associated with follow-up  
 
Follow-up 
Attendees 
(n=588) 
  
Non Follow-
up     
Attendees 
(n=394)       
  n %   n % 
OR 
unadjusted 95% CI 
p-
value* 
OR† 
adjusted 95% CI 
p-
value*
Health status            <0.001    0.229
   excellent/ very good 356 54.0   303 46.1 1.00    1.00   
   good 193 71.0   79 29.0 2.08 [1.54-2.82]   1.40 [0.95-2.05]  
   fair/ poor 29 70.7   12 29.3 2.06 [1.03-4.10]   1.15 [0.46-2.87]  
Bodily pain     <0.001  0.113
   none 378 54.9  310 45.1 1.00  1.00 
   very mild 91 75.2  30 24.8 2.49 [1.60-3.86]  1.80 [1.10-2.95]
   mild 49 64.5  27 35.5 1.49 [0.91-2.44]  1.09 [0.59-1.98]
   moderate/severe 55 70.5  23 29.5 1.96 [1.18-3.26]  1.33 [0.68-2.59]
Self reported late effects           <0.001    <0.001
   No 300 49.4   213 48.1 1.00    1.00   
   Yes 281 76.4   87 23.8 3.31 [2.48-4.41]   2.50 [1.77-3.53]  
Received medical record 
or checklist 
 
  0.001  0.074
   No 473 57.3  353 42.8 1.00  1.00 
   Yes 115 73.7  41 27.2 2.09 [1.43-3.07]  1.37 [0.97-1.94]
Sought for further 
information           <0.001    <0.001
   No 230 51.9   213 48.1 1.00    1.00   
   Yes 308 67.8   146 32.2 1.95 [1.49-2.56]   1.78 [1.31-2.40]  
Partner      0.192   
  No 437 58.2  314 41.8 1.00   
  Yes 135 64.6  74 35.4 0.84 [0.64-1.09]   
Own education           0.255     
  compulsory schooling 44 68.8   20 31.3 1.65 [0.94-2.89]       
  vocational training 248 57.1   186 42.9 1.00        
  upper secondary‡ 154 59.9   103 40.1 1.12 [0.82-1.53]       
  university education 92 65.2   49 34.8 1.41 [0.95-2.09]       
  
Abbreviations: OR, Odds Ratio; CI, Confidence Interval 
Row percentages are presented 
* Global p-value 
† Adjusted for all factors listed and for sex, age at diagnosis, time since diagnosis and diagnosis 
‡ Upper secondary education includes high school, teachers training colleges, technical colleges and upper vocational 
education 
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APPENDIX 
The Swiss Paediatric Oncology Group (SPOG): Dr. med. R. Angst, Aarau; Prof. Dr. 
med. M Paulussen, V. Stahel, Basel; Prof. Dr. med A. Hirt, K. Zimmermann, Bern; PD 
Dr. med A. H. Ozsahin, M. Berner, Geneva; PD Dr. med M. Beck Popovic, Dr. med. 
E. Garcia, Lausanne; Dr. med L. Nobile Buetti, Locarno; Dr. Med. Pierluigi Brazzola, 
Bellinzona; Dr. med U. Caflisch, Y. Bonetti, Lucerne; Dr. med J. Greiner, Dr. med. H. 
Hengartner, F. Hochreutner, St. Gallen; Prof. Dr. med. M. Grotzer, H. Markiewicz 
Zürich.  
 
 
 
 
